A Study of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS Paliperidone
Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of an organic cation transporter
inhibitor, trimethoprim, on the pharmacokinetics of orally administered ER OROS paliperidone
and to assess the safety and tolerability of the treatments in healthy male volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.